→
Thermo Fisher Scientific (TMO) is positioned for growth with a current price of $492.51, reflecting a 1.09% increase today. The company's P/E ratio stands at 26.73, which is reasonable given its EPS growth of 6.66% year-over-year. With a market cap of $183.03B and a robust revenue growth of 5.36%, TMO demonstrates solid fundamentals, particularly as it continues to beat earnings estimates consistently, including a recent Q1 2026 beat of $5.44 against an estimate of $5.29.
Investors should consider a buy position in TMO given its solid fundamentals and consistent earnings performance.
Thermo Fisher's robust performance, with an average of 11 Strong Buy ratings from analysts, suggests significant upside potential. The company's ability to continually beat earnings estimates, such as a Q1 2026 earnings of $5.44, positions it strongly against competitors within the Life Sciences Tools & Services sector.
Despite the positive earnings outlook, Thermo Fisher's price has seen a 23.5% decline from its 52-week high of $643.99, indicating potential weakness in market sentiment. Additionally, with a beta of 0.88, the stock exhibits lower volatility than the market, yet this could limit rapid growth in a bullish environment.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Helm's AI rates TMO as Bullish. Investors should consider a buy position in TMO given its solid fundamentals and consistent earnings performance.
Despite the positive earnings outlook, Thermo Fisher's price has seen a 23.5% decline from its 52-week high of $643.99, indicating potential weakness in market sentiment. Additionally, with a beta of 0.88, the stock exhibits lower volatility than the market, yet this could limit rapid growth in a bullish environment.
Thermo Fisher's robust performance, with an average of 11 Strong Buy ratings from analysts, suggests significant upside potential. The company's ability to continually beat earnings estimates, such as a Q1 2026 earnings of $5.44, positions it strongly against competitors within the Life Sciences Tools & Services sector.
Thermo Fisher Scientific (TMO) is positioned for growth with a current price of $492.51, reflecting a 1.09% increase today. The company's P/E ratio stands at 26.73, which is reasonable given its EPS growth of 6.66% year-over-year. With a market cap of $183.03B and a robust revenue growth of 5.36%, TMO demonstrates solid fundamentals, particularly as it continues to beat earnings estimates consistently, including a recent Q1 2026 beat of $5.44 against an estimate of $5.29.
Thermo Fisher Scientific (TMO) is positioned for growth with a current price of $492.51, reflecting a 1.09% increase today. The company's P/E ratio stands at 26.73, which is reasonable given its EPS growth of 6.66% year-over-year. With a market cap of $183.03B and a robust revenue growth of 5.36%, TMO demonstrates solid fundamentals, particularly as it continues to beat earnings estimates consistently, including a recent Q1 2026 beat of $5.44 against an estimate of $5.29. Our overall verdict is Bullish.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for TMO at helmterminal.dev/analyze/TMO, updated continuously during US market hours. No signup required.